These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 3092937)
1. Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease. Puri VK; Rawat A; Sharma A; Mehrotra A; Hasan M; Shanker K; Verma M; Sinha JN; Bhargava KP Br Med J (Clin Res Ed); 1986 Sep; 293(6547):591-3. PubMed ID: 3092937 [TBL] [Abstract][Full Text] [Related]
2. A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone. Kubik MM; Richardson SG Postgrad Med J; 1987 May; 63(739):351-6. PubMed ID: 3118351 [TBL] [Abstract][Full Text] [Related]
3. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment. Cortellaro M; Boschetti C; Antoniazzi V; Moreo G; Repetto S; Verna E; Boscarini M; Limido A; Binaghi G; Polli EE Thromb Haemost; 1983 Dec; 50(4):857-9. PubMed ID: 6665767 [TBL] [Abstract][Full Text] [Related]
4. Failure of sulphinpyrazone to affect platelet survival in patients with rheumatic heart valvular disease: a double blind study using 75Se-methionine labeled platelets. Fabris F; Casonato A; Randi ML; Schivazappa L; Schiavinato L; Girolami A Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(4):594-601. PubMed ID: 6196274 [TBL] [Abstract][Full Text] [Related]
5. Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function. Wilcox RG; Richardson D; Hampton JR; Mitchell JR; Banks DC Br Med J; 1980 Aug; 281(6239):531-4. PubMed ID: 7000264 [TBL] [Abstract][Full Text] [Related]
6. Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study. Lancet; 1982 Jan; 1(8266):237-42. PubMed ID: 6120272 [TBL] [Abstract][Full Text] [Related]
7. Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone. Cortellaro M; Boschetti C; Fassio G; Baroni L; Polli EE Acta Haematol; 1981; 65(3):193-204. PubMed ID: 6785974 [TBL] [Abstract][Full Text] [Related]
8. Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone. Cade JF; Doyle DJ; Chesterman CN; Morgan FJ; Rennie GC Circulation; 1982 Jul; 66(1):29-32. PubMed ID: 6211296 [TBL] [Abstract][Full Text] [Related]
9. Platelet serotonergic mechanisms in ischaemic heart disease. Puri VK; Verma M; Saxena AK; Shanker K Thromb Res; 1990 Feb; 57(3):445-51. PubMed ID: 2315895 [TBL] [Abstract][Full Text] [Related]
10. Aspirin and other platelet-aggregation inhibiting drugs. Gallus AS Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861 [TBL] [Abstract][Full Text] [Related]
11. Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction. Lijnen P; Boelaert J; van Eeghem P; Daneels R; Schurgers M; de Jaegere P; van der Stichele E; Vincke J; Fagard R; Verschueren LJ; Amery A Clin Nephrol; 1983 Mar; 19(3):143-6. PubMed ID: 6340878 [TBL] [Abstract][Full Text] [Related]
12. A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction. Cortellaro M; Boschetti C; Fassio G; Basagni M; Polli EE Acta Haematol; 1979; 61(2):68-74. PubMed ID: 217218 [TBL] [Abstract][Full Text] [Related]
13. A critical appraisal of the clinical efficiency of anti-platelet drugs. Lecompte T; Samama M Agents Actions Suppl; 1986; 20():203-14. PubMed ID: 3544741 [No Abstract] [Full Text] [Related]
14. Controlled ex-vivo effect of sulfinpyrazone on platelet function of myocardial infarction patients. Cortellaro M; Fassio G; Boschetti C; Basagni M; Polli EE Haematologica; 1979 Apr; 64(2):173-89. PubMed ID: 112008 [No Abstract] [Full Text] [Related]